Highlights Shilpa Medicare Limited NSE India S.E.

Equities

SHILPAMED

INE790G01031

Delayed NSE India S.E. Other stock markets 01:51:31 2024-05-02 am EDT			5-day change	1st Jan Change
547.3 ^INR	-0.55%		+2.11%	+65.40%

Apr. 18	Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	MT
Apr. 17	Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	Apr. 18	MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	Apr. 17	MT
Shilpa Medicare Gets Board Nod to Launch QIP	Apr. 09	MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA	Mar. 01	MT
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe	Feb. 26	MT
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug	Jan. 19	MT
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Shilpa Medicare Acquires US-Based Pilnova Pharma	Nov. 02	MT
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal	23-10-11	CI
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection	23-09-04	MT
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms	23-09-04	MT
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg	23-09-01	CI
Shilpa Medicare's Manufacturing Facility in Telangana Gets Clearance from Brazilian Regulator	23-08-25	MT
Shilpa Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Shilpa Medicare Gets Regulatory Nod for Pemetrexed Injections	23-07-31	MT
Shilpa Medicare Limited Receives Approval from CDSCO, New Delhi for Manufacturing and Sale of Lenvatinib Capsules, 12, 18 and 24 mg in India	23-06-29	CI
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-25	CI
Shilpa Medicare Limited Announces New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 mg/50 mg & 100 mg/10 mg/10 mgl, Ready to Use Form Form Formulation Is Approved By US FDA	23-05-23	CI
Shilpa Medicare Gets US FDA Nod for Apremilast Tablets	23-04-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shilpa Medicare Limited NSE India S.E.

Equities

SHILPAMED

INE790G01031

Highlights

Filters